Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak

S. H. Lee; J. J. Yim; H. J. Kim; T. S. Shim; H. S. Seo; Y. S. Cho; H. K. Lee; Y. M. Lee; E. J. Lee; W. J. Lew

doi:10.1017/S0950268811001476

Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak

S. H. Lee, J. J. Yim, H. J. Kim, T. S. Shim, H. S. Seo, Y. S. Cho, H. K. Lee, Y. M. Lee, E. J. Lee, W. J. Lew

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

We screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST+/IGRA+ (n=101), TST+/IGRA- (n=22), TST-/IGRA+ (n=16), and TST-/IGRA- (n=41). RFP treatment (4 months) was prescribed only to the TST+/IGRA+ group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24·1%) including hepatotoxicity (11·5%), flu-like syndrome (5·7%), and thrombocytopenia (3·4%). TB developed in two TST+/IGRA+ subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21·8 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis.

Original language	English
Pages (from-to)	1028-1035
Number of pages	8
Journal	Epidemiology and Infection
Volume	140
Issue number	6
DOIs	https://doi.org/10.1017/S0950268811001476
Publication status	Published - 2012 Jun
Externally published	Yes

Keywords

Antibiotic prophylaxis
drug toxicity
multidrug-resistant tuberculosis
rifampicin
tuberculosis

ASJC Scopus subject areas

Epidemiology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1017/S0950268811001476

Cite this

@article{550a36f33bad44d0a24ffb77ed240cba,

title = "Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak",

abstract = "We screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST+/IGRA+ (n=101), TST+/IGRA- (n=22), TST-/IGRA+ (n=16), and TST-/IGRA- (n=41). RFP treatment (4 months) was prescribed only to the TST+/IGRA+ group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24·1%) including hepatotoxicity (11·5%), flu-like syndrome (5·7%), and thrombocytopenia (3·4%). TB developed in two TST+/IGRA+ subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21·8 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis.",

keywords = "Antibiotic prophylaxis, drug toxicity, multidrug-resistant tuberculosis, rifampicin, tuberculosis",

author = "Lee, {S. H.} and Yim, {J. J.} and Kim, {H. J.} and Shim, {T. S.} and Seo, {H. S.} and Cho, {Y. S.} and Lee, {H. K.} and Lee, {Y. M.} and Lee, {E. J.} and Lew, {W. J.}",

year = "2012",

month = jun,

doi = "10.1017/S0950268811001476",

language = "English",

volume = "140",

pages = "1028--1035",

journal = "Epidemiology and Infection",

issn = "0950-2688",

publisher = "Cambridge University Press",

number = "6",

}

TY - JOUR

T1 - Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak

AU - Lee, S. H.

AU - Yim, J. J.

AU - Kim, H. J.

AU - Shim, T. S.

AU - Seo, H. S.

AU - Cho, Y. S.

AU - Lee, H. K.

AU - Lee, Y. M.

AU - Lee, E. J.

AU - Lew, W. J.

PY - 2012/6

Y1 - 2012/6

N2 - We screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST+/IGRA+ (n=101), TST+/IGRA- (n=22), TST-/IGRA+ (n=16), and TST-/IGRA- (n=41). RFP treatment (4 months) was prescribed only to the TST+/IGRA+ group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24·1%) including hepatotoxicity (11·5%), flu-like syndrome (5·7%), and thrombocytopenia (3·4%). TB developed in two TST+/IGRA+ subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21·8 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis.

AB - We screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST+/IGRA+ (n=101), TST+/IGRA- (n=22), TST-/IGRA+ (n=16), and TST-/IGRA- (n=41). RFP treatment (4 months) was prescribed only to the TST+/IGRA+ group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24·1%) including hepatotoxicity (11·5%), flu-like syndrome (5·7%), and thrombocytopenia (3·4%). TB developed in two TST+/IGRA+ subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21·8 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis.

KW - Antibiotic prophylaxis

KW - drug toxicity

KW - multidrug-resistant tuberculosis

KW - rifampicin

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84861094516&partnerID=8YFLogxK

U2 - 10.1017/S0950268811001476

DO - 10.1017/S0950268811001476

M3 - Article

C2 - 21835069

AN - SCOPUS:84861094516

SN - 0950-2688

VL - 140

SP - 1028

EP - 1035

JO - Epidemiology and Infection

JF - Epidemiology and Infection

IS - 6

ER -

Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this